The Alzheimer’s research landscape is undergoing a fundamental transformation. With disease-modifying therapies now a reality, sponsors must rethink how they design, recruit for, and execute trials—particularly in early-stage and preclinical populations.
This guide explores five strategic imperatives that can help trial teams navigate scientific and operational complexities, integrate emerging diagnostics, and stay ahead of regulatory shifts in this high-stakes, rapidly evolving field.